151 related articles for article (PubMed ID: 38762492)
1. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
[TBL] [Abstract][Full Text] [Related]
3. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
4. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
[TBL] [Abstract][Full Text] [Related]
5. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
[TBL] [Abstract][Full Text] [Related]
6. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
7. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
[TBL] [Abstract][Full Text] [Related]
8. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
[TBL] [Abstract][Full Text] [Related]
9. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
10. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
11. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
Front Immunol; 2021; 12():673912. PubMed ID: 34108971
[TBL] [Abstract][Full Text] [Related]
12.
Zhu Q; Wang H; Chai S; Xu L; Lin B; Yi W; Wu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2216796120. PubMed ID: 36943877
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1α via Chaperone-Mediated Autophagy.
Matsui C; Deng L; Minami N; Abe T; Koike K; Shoji I
J Virol; 2018 Jul; 92(13):. PubMed ID: 29695419
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Tseng YJ; Lee CH; Chen WY; Yang JL; Tzeng HT
J Invest Dermatol; 2021 Nov; 141(11):2690-2698.e6. PubMed ID: 34000287
[TBL] [Abstract][Full Text] [Related]
15. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Tang T; Huang X; Zhang G; Lu M; Hong Z; Wang M; Huang J; Zhi X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288467
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 as a master regulator of PD-L1.
Yaseen MM; Abuharfeil NM; Darmani H
Cancer Immunol Immunother; 2022 Oct; 71(10):2325-2340. PubMed ID: 35294592
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
